Financials BIONOMICSSADR Nasdaq

Stocks

Market Closed - Nasdaq 16:00:00 2024-12-23 EST			5-day change	1st Jan Change
0.2531 ^USD	+4.20%		-.--%	-

07-23	Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $35 million.	CI
07-23	Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell	MT

Fiscal Period: June	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	5.581	5.49	0.5996	3.513	23.79	-	-	-
Change	-	-1.64%	-89.08%	485.9%	577.2%	-	-	-
EBITDA ¹	-5.74	-20.8	-30.87	-26.17	-1.717	-23.16	-26.31	-30.74
Change	-	-262.35%	-48.42%	15.21%	93.44%	-1,249.38%	-13.58%	-16.85%
EBIT ¹	-7.441	-21.91	-32.02	-27.18	-1.717	-23.16	-26.31	-30.74
Change	-	-194.43%	-46.18%	15.13%	93.68%	-1,249.38%	-13.58%	-16.85%
Interest Paid	-1.444	-0.0442	-0.0292	-	-	-	-	-
Earnings before Tax (EBT) ¹	-	-21.95	-32.05	-23.67	-1.274	-28.31	-24.88	-29.45
Change	-	-	-46.02%	26.17%	94.62%	-2,122.12%	12.12%	-18.39%
Net income ¹	-	-21.76	-31.85	-23.53	-0.562	-27.6	-24.59	-29.17
Change	-	-	-46.36%	26.11%	97.61%	-4,810.58%	10.88%	-18.6%
Announcement Date	8/25/21	8/25/22	9/29/23	11/8/24	9/29/25	-	-	-

¹AUD in Million

Estimates

Fiscal Period: June	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4
Net sales ¹	0.08	0.08	-	-	-	-	1.042	23.44	-0.0202	-	-	-	-	-	-	-	-
Change	-	0%	-	-	-	-	-	2,149.45%	-100.09%	-	-	-	-	-	-	-	-
EBITDA ¹	-	-	-	-	-	-	-5.561	18.97	-8.871	-8.377	-5.514	-1.463	-5.147	-	-	-	-
Change	-	-	-	-	-	-	-	441.15%	-146.76%	5.56%	34.18%	73.47%	-251.77%	-	-	-	-
EBIT	-5.79	-5.79	-3.01	-3.01	-7.41	-	-	18.71	-8.871	-8.631	-5.749	-	-	-	-	-	-
Change	-	0%	48.01%	0%	-146.18%	-	-	-	-147.4%	2.71%	33.39%	-	-	-	-	-	-
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-6.57	-6.57	-4.4	-4.4	-8.16	-	-3.037	17.47	-13.91	-15.18	2.59	-0.7552	-4.861	-	-	-	-
Change	-	0%	33.03%	0%	-85.45%	-	-	675.23%	-179.63%	-9.11%	117.06%	-129.16%	-543.66%	-	-	-	-
Net income ¹	-6.53	-6.53	-4.35	-4.35	-8.1	-1.241	-3.055	17.6	-13.51	-15.13	2.639	-0.7065	-4.575	-	-	-	-
Change	-	0%	33.38%	0%	-86.21%	84.68%	-146.22%	675.95%	-176.75%	-11.99%	117.45%	-126.77%	-547.53%	-	-	-	-
Announcement Date	2/23/23	2/23/22	8/25/22	8/25/22	2/23/23	11/14/24	2/14/25	5/20/25	9/29/25	11/14/25	2/17/26	5/15/26	-	-	-	-	-

¹AUD in Million

Estimates

Fiscal Period: June	2022 S1	2022 S2	2023 S1	2023 S2	2024 S1	2024 S2
Net sales ¹	-0.66	6.15	0.7395	-0.1399	-	3.69
Change	-	1,031.73%	-87.98%	-118.91%	-	-
EBITDA	-11.11	-5.57	-	-	-	-
Change	-	49.86%	-	-	-	-
EBIT	-	-	-16.3	-15.73	-	-
Change	-	-	-	3.49%	-	-
Charge d'intérêts	-0.026	-0.0182	-	-0.0141	-	-
Earnings before Tax (EBT) ¹	-	-	-16.31	-15.74	-	-0.1586
Change	-	-	-	3.49%	-	-
Net income ¹	-	-	-16.21	-15.64	-15.37	-0.1879
Change	-	-	-	3.51%	1.73%	98.78%
Announcement Date	2/23/22	8/25/22	2/23/23	9/29/23	3/15/24	11/8/24

¹AUD in Million

Estimates

Fiscal Period: June	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Announcement Date	8/25/21	8/25/22	9/29/23	11/8/24	9/29/25	-	-	-

Estimates

Fiscal Period: June	2020	2021	2022	2023	2024	2025
CAPEX ¹	0.007704	0.001468	0.001544	-	-	-
Change	-	-80.94%	5.18%	-	-	-
Free Cash Flow (FCF) ¹	0.3851	-2.86	-11.89	-7.178	-7.925	0.4617
Change	-	-842.67%	-315.64%	39.62%	-10.42%	105.83%
Announcement Date	8/28/20	8/25/21	8/25/22	9/29/23	9/30/24	9/29/25

¹USD in Million

Estimates

Fiscal Period: June	2020	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	-	-102.84%	-378.84%	-5,147.68%	-744.93%	-7.21%	-	-	-
EBIT Margin (%)	-	-133.31%	-399.05%	-5,340.62%	-773.59%	-7.21%	-	-	-
EBT Margin (%)	-	-	-399.85%	-5,345.5%	-673.59%	-5.35%	-	-	-
Net margin (%)	-	-	-396.36%	-5,311.01%	-669.82%	-2.36%	-	-	-
FCF margin (%)	-	-	-	-3,559.36%	-	-	-	-	-
FCF / Net Income (%)	-	-	-	67.02%	-	-	-	-	-
Profitability
ROA	-11.5%	-14.48%	-18.4%	-32.11%	-39.58%	-1.84%	-	-	-
ROE	-39.88%	-28.86%	-41.64%	-70.72%	-78.44%	-2.03%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	-	-	-	-	-	-	-
CAPEX / EBITDA (%)	-	-	-	-	-	-	-	-	-
CAPEX / FCF (%)	-	-	-	-	-	-	-	-	-
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EPS ¹	-	-	-	-	-	-0.23	-4.07	-2.43	-2.46
Change	-	-	-	-	-	-	-1,669.57%	40.29%	-1.23%
Nbr of stocks (in thousands)	-	-	-	-	-	1,880	5,405	5,405	5,405
Announcement Date	-	-	-	-	-	9/29/25	-	-	-